The side population (SP) in human lung cancer cell lines and tumors is enriched with cancer stem cells. An endogenous inhibitor of angiogenesis known as tissue inhibitor of matrix metalloproteinase-2 (TIMP-2), characterized for its ability to inhibit matrix metalloproteinases (MMPs), has been shown by several laboratories to impede tumor progression through MMP-dependent or -independent mechanisms. We recently reported that forced expression of TIMP-2, as well as the modified form Ala þ TIMP-2 (that lacks MMP inhibitory activity) significantly blocks growth of A549 human lung cancer cells in vivo. However, the mechanisms underlying TIMP-2 antitumor effects are not fully characterized. Here, we examine the hypothesis that the TIMP-2 antitumor activity may involve regulation of the SP in human lung cancer cells. Indeed, using Hoechst dye efflux assay and flow cytometry, as well as quantitative reverse transcriptase-PCR analysis, we found that endogenous TIMP-2 mRNA levels showed a significant inverse correlation with SP fraction size in six non-small cell lung cancer cell lines. In A549 cells expressing increased levels of TIMP-2, a significant decrease in SP was observed, and this decrease was associated with lowered gene expression of ABCG2, ABCB1 and AKR1C1. Functional analysis of A549 cells showed that TIMP-2 overexpression increased chemosensitivity to cytotoxic drugs. The SP isolated from TIMP-2-overexpressing A549 cells also demonstrated impaired migratory capacity compared with the SP from empty vector control. More importantly, our data provide strong evidence that these TIMP-2 functions occur independent of MMP inhibition, as A549 cells overexpressing Ala þ TIMP-2 exhibited identical behavior to those overexpressing TIMP-2 alone. Our findings provide the first indication that TIMP-2 modulates SP phenotype and function, and suggests that TIMP-2 may act as an endogenous suppressor of the SP in human lung cancer cells.
INTRODUCTION
Solid tumors often exhibit functional heterogeneity, and contain cells with distinct proliferative and differentiation potential. 1 An accepted model accounting for variation in the regenerating capacity of tumors is that of the cancer stem cell (CSC). 2 Numerous investigations have demonstrated that solid tumors contain a small sub-population of CSCs with properties of self-renewal, multidrug resistance and metastatic potential. Cell surface markers such as CD133, CD44, CD24, TACSTD1 and STHY1 have proved useful for the isolation of cell subsets enriched for CSCs. 3 In addition, a sub-population of cells referred to as the side population (SP) were isolated using the Hoechst 33342 dye efflux assay and shown to contain CSCs. 4 The SP was first identified by Goodell et al., 5 as a population of cells enriched with hematopoietic stem cells isolated from the murine bone marrow. SP exhibit stem cell characteristics and has been reported in a number of human cancers such as cervix, thyroid, ovary, glia and hepatic oval cells. [6] [7] [8] [9] [10] A recent study demonstrated that the SP existed in both human lung cancer tissues and lung cancer cell lines, and was enriched with tumorinitiating capability in vivo. In addition, the SP showed a higher potential for invasiveness and resistance to chemotherapy in vitro, compared with non-SP cells. 11 The SP phenotype is characterized by the expression of adenosite triphosphate (ATP)-binding cassette transporters (ABC transporters), a family of proteins that uses cellular ATP hydrolysis to drive the transport of various substrates, including drugs, metabolites and other compounds, across cell membranes. 12 More specifically, ABCG2, one of the main ABC transporters, is an important molecular determinant of the SP phenotype because of its high efficiency for effecting Hoechst dye efflux. 13 ABCG2 is expressed in stem cell populations derived from a wide range of normal and tumor tissues.
14 ABCG2, together with another two members of the ABC transporter family, namely ABCB1 and ABCC1, are overexpressed in multiple cancers and participate in tumor resistance to chemotherapy by actively transporting drugs outside the cell membrane. 15 The activities of ABCG2, and other ABC transporters are important indicators of CSCs activity in various solid tumors. 16 Tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) belongs to the TIMP family of proteins that comprises four members (TIMP-1, 2, 3 and 4). TIMPs are multifunctional proteins, well known for the ability to regulate extracellular matrix degradation by inhibiting the proteolytic activities of matrix metalloproteinases (MMPs). Physiologically, TIMP-2 is ubiquitously expressed in most non-neoplastic cell types, however, its non-MMP related functions are impaired during tumor growth as MMP levels are dramatically increased and free TIMP-2 levels drop. TIMP-2 is able to directly inhibit angiogenesis independently of MMP inhibition through unique mechanisms that involve binding to endothelial cell surface receptors, integrin a3b1 and insulin-like growth factor 1 receptor. [17] [18] [19] We recently reported that forced expression of TIMP-2 (A549 T2) and a modified form known as Ala þ TIMP-2 (A549 AT2, devoid of MMP inhibitory activity) significantly inhibited migration and invasion of human A549 lung cancer cells in vitro and suppressed tumor growth in vivo. Further studies demonstrated that decreased tumor growth was associated with reduced angiogenesis, increased apoptosis, and decreased activation of focal adhesion kinase and AKT signaling pathways in A549 T2 and AT2 xenograft tumors compared with controls. 20 These findings reveal that TIMP-2 directly influences tumor cell signaling pathways in addition to its well-characterized antiangiogenic effects. In this study, we examined the influence of TIMP-2 on the CSC population in a variety of human lung cancer cells in vitro. Our data show a significant inverse correlation between endogenous TIMP-2 mRNA levels and the percentage of SP contained within six independent lung cancer cell lines. These results led us to examine the effects of TIMP-2 and Ala þ TIMP-2 on SP phenotype and functionality, as well as the SP-associated genes expressed in human lung cancer A549 cells.
RESULTS AND DISCUSSION
Endogenous TIMP-2 gene expression levels inversely correlate with SP percentage in six non-small cell lung cancer cell lines We analyzed SP percentage and endogenous TIMP-2 expression in six non-small cell lung cancer cell lines, A549, H23, H460, H322M, H522 and H358M. The SP in A549, H23, H460 and H322M cell lines, gated in the dim fluorescence area of Hoechst dye, was analyzed by flow cytometry (Figure 1a, upper panel) . In the presence of an ABC transporter inhibitor, verapamil, the SP was significantly diminished (Figure 1a , lower panel). We also characterized the (Figure 1c) . Surprisingly, there was a statistically significant inverse correlation between endogenous TIMP-2 mRNA expression levels and SP percentage in these six lung cancer cell lines (Figures 1b, c and e) . We also measured extracellular TIMP-2 protein levels as shown in Figure 1d . Secreted TIMP-2 protein levels correlate significantly with TIMP-2 mRNA levels (Supplementary Figure S1a) , although the inverse correlation with SP data did not reach statistical significance (data not shown). Intracellular TIMP-2 protein levels were undetectable by western blot in these cell lines (data not shown). Although there is no statistically significant correlation between ABCG2 mRNA expression ( Figure 1f ) and TIMP-2 mRNA expression (Figure 1d ) in these lung cancer cell lines, we could see the general trend of lower ABCG2 levels in higher TIMP-2-expressing cell lines, which had lower percentages of SP. We also analyzed the ABCG2 protein levels in these cell lines and they significantly correlated with the mRNA levels ( Figure 1g and Supplementary Figure S1b) . Although ABCG2 is the main determining factor for the detection of SP, other members of multidrug ABC transporter family also contribute to this phenotype.
Increased TIMP-2 or Ala þ TIMP-2 expression significantly decreases SP, ABCG2 expression, and regulates other SP-associated genes in A549 cells In order to test the hypothesis that TIMP-2 affects the phenotypic and functional properties of SP in lung cancer cells, we performed flow cytometric analysis of the SP in A549 cell cultures. Mixtures of stable, retrovirally transfected A549 cells, expressing TIMP-2, Ala þ TIMP-2, and empty vector (EV) as control, were generated and characterized previously. 20 The SP fractions in A549 T2 (2.8%) and AT2 (2.7%) cell lines were significantly (B3-fold) lower compared with the EV control (8.2%; Figures 2a and b) . Complementary DNA microarray analysis of differential gene expression in A549 T2, AT2 and EV control cell lines identified a statistically significant decrease in ABCG2 (false discovery rate ¼ 0) (Figure 2c ), a molecular determinant of the SP phenotype. 13 Analysis of two other members of the multidrug ABC transporter family, ABCB1 and ABCC1, revealed that ABCB1 expression was also decreased (not statistically significantly) in A549 T2 and AT2 cell lines compared with EV control, however, no detectable difference in ABCC1 levels was found using both probes for ABCC1. In contrast, AKR1C1, a gene related to drug resistance and marker for A549 SP, 21 was significantly downregulated in the microarray All the cell lines were grown according to the manufacturer's instructions. Cells (1 Â 10 6 / ml) were preincubated with or without 50 mM of the ABC transporter inhibitor verapamil (Sigma-Aldrich, St Louis, MO, USA) in prewarmed Dulbecco's modified Eagle's medium/F-12 media 1:1 (Invitrogen, Carlsbad, CA, USA) with 2% fetal bovine serum (FBS) (HyClone, Logan, UT, USA) and 10 mM HEPES buffer (GIBCO, Carlsbad, CA, USA) at 37 1C for 30 min. Hoechst 33342 dye was added at a final concentration of 5 mg/ml and cells were incubated for another 90 min at 37 1C with intermittent shaking. At the end of incubation, cells were put on ice for 5 min, and washed with ice-cold HBSS (GIBCO) with 2% FBS and 10 mM HEPES buffer. After spun down at 4 1C, cells were resuspended in the same washing buffer. Propidium iodide (Roche Diagnostics, Indianapolis, IN, USA) at a final concentration of 2 mg/ml was added to exclude dead cells before FACS analysis. The Hoechst dye was excited with the near UV laser at 375 nm and its fluorescence was measured with a 450/20 BP filter for Hoechst blue, 670 LP filter for Hoechst red, and a 610 DM LP filter between the two detectors. Analysis and sorting were performed using FACSAria II (Becton Dickinson, Franklin Lakes, NJ, USA). SP was gated based on the theory that over 90% of the cells would disappear in the presence of inhibitor (verapamil). The data were presented as the means ± s.e.m. of three independent experiments. (c, f) Real-time quantitative reverse transcriptase (qRT)-PCR analysis for TIMP-2 and ABCG2 in six lung cancer cell lines. Total RNA was extracted using RNeasy kit (Qiagen), and 2 mg were subsequently reverse transcribed using the SuperScript First Strand Synthesis system (Invitrogen) according to the manufacturer's instructions. TIMP-2 and GAPDH primer sequences for quantitative real-time RT-PCR were previously described. 20 Taqman gene expression assays (Applied Biosystems, Carlsbad, CA, USA) were used for ABCG2. Mean CT values for target genes were normalized to mean CT values for the endogenous control GAPDH. The ratio of mRNA expression of target gene versus glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was defined as 2( À DCt). All data are the means±s.e.m. of at least three independent experiments. (d) Secreted TIMP-2 protein levels in six lung cancer cell lines. Cells (3 Â 10 5 / ml) were seed into six-well plates. After 24 h, cells were changed to serum-free medium, and incubated for another 36 h. The cell supernatant was collected. The secreted TIMP-2 levels in the supernatant was measured by TIMP-2 ELISA (Calbiochem, La Jolla, CA, USA). The final TIMP-2 concentration was adjusted to the number of cells. The result was presented with means ± s.e.m. of three replicates. (e) Statistically significant inverse correlation between TIMP-2 mRNA expression and SP percentage in six lung cancer cell lines. (g) Western blot analysis of ABCG2 protein in six lung cancer cell lines. About 45 mg of cell lysate, extracted from each cells lines, were subjected to western blot analysis and probed with mouse monoclonal anti-ABCG2 (Santa Cruz, Santa Cruz, CA, USA, sc-58222) and anti-actin (Calbiochem, CP01) antibodies. Relative band intensities for each cell line were shown in chart part using densitometry analysis (ImageJ software, NIH, Bethesda, MD, USA). Actin is the loading control. All the calculations were done with the GraphPad Prism software (Irvine, CA, USA) here and after. Figure 1 . A549 cell lines, which stably overexpress TIMP-2 (T2), Ala þ TIMP-2 (AT2) and EV control were described in our previous study. 20 The experiment was repeated at least three times. (c) Heatmap of genes (ABCG2, ABCB1, ABCC1 and AKR1C1) was generated from complementary DNA microarray analysis of differential gene expression in A549 cell lines. RNA from three A549 cell lines represented in three independent biological replicates was extracted using the Rneasy kit (Qiagen). RNA quality was analyzed using Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) and NanoDrop (ThermoScientific, Pittsburgh, PA, USA). About 100 ng of total RNA was reversed transcribed and labeled with biotin. Samples were hybridized to Affymetrix GeneChip U133plus2.0 arrays (Affymetrix, Santa Clara, CA, USA). Raw data were processed using the R/ Bioconductor Statistical Package. A 'Multiclass' Significance of Microarray analysis was used. False discovery rate cutoff of 0.10 (10%) was used to generate a list of differentially expressed genes. Heatmaps were generated using Cluster and Treeview analyses. (d-g) Quantitative reverse transcriptase (qRT)-PCR and western blot analysis for ABCG2, ABCB1, ABCC1 and AKR1C1 expression in A549 cell lines. qRT-PCR was performed as described in Figure 1 . Taqman gene expression assays (Applied Biosystems) were used for ABCG2, ABCB1, ABCC1 and AKR1C1. All data are the means ± s.e.m. of at least three independent experiments. Statistical analysis using Student's t-test was applied between groups. *Po0.05, **Po0.01, ***Po0.001 as compared with EV. Western blot analysis of ABCG2, ABCB1, ABCC1 and AKR1C1 protein levels in A549 cell lines was performed and analyzed as Figure 1 . About 15 mg of cell lysate was loaded. Primary antibodies ABCB1 (Santa Cruz, sc-55510), ABCC1 (Santa Cruz, 18835), AKR1C1(Abnova, Walnut, CA, USA, H00001645-B01p) and anti-GAPDH (Santa Cruz, sc-32233) antibodies were applied. ABCB1, ABCC1 and AKR1C1 shared same glyceraldehyde 3-phosphate dehydrogenase (GAPDH) loading control.
Based on at least three independent experiments, the ABCG2 and ABCB1 mRNA levels were significantly reduced in both A549 T2 and AT2, whereas, once again no difference for ABCC1 was observed (Figures 2d-f) . Interestingly, AKR1C1 was significantly downregulated in AT2, whereas average AKR1C1 mRNA levels in the T2 cell line was only somewhat lower than the EV control (Figure 2g ). We further analyzed the protein levels of these genes by western blot (Figures 2d-f) . As shown below each graph for the mRNA levels, the protein levels of these genes are consistent with the mRNA levels in EV, T2 and AT2 cell lines. Especially for AKR1C1, the protein levels confirmed that T2 significantly suppressed AKR1C1 expression. In summary, the data suggest that enhanced TIMP-2 and Ala þ TIMP-2 expression is associated with a significant decrease in the size of the SP and suppression of the expression of genes, such as ABCG2 and AKR1C1, specifically related to the A549 SP phenotype.
Enhanced TIMP-2 or Ala þ TIMP-2 expression increases A549 chemosensitivity to cytotoxic drugs ABCG2 is an important transporter for a wide variety of cytotoxic chemotherapeutic drugs. Therefore, we investigated whether the TIMP-2-induced decrease in ABCG2 expression at a functional level results in an increase in chemosensitivity of A549 cells to cytotoxic drugs. Flow cytometric analysis of ABCG2 cell surface protein expression showed that the geometric mean fluorescence of ABCG2-expressing cells in A549 T2 and AT2 cells (103 and 95, respectively) was less than EV control (168; Figure 3a) , consistent with our previous western blot results (Figure 2d ). We then evaluated the uptake of two very specific ABCG2 substrates, Hoechst dye and anticancer drug topotecan in A549 cells with different levels of ABCG2. As shown in Figure 3b , there is dramatic increase in Hoechst uptake in T2 and AT2 cell lines compared with EV, which indicated high ABCG2 levels not only affected proportion of SP, also significantly increased Hoechst accumulation in the whole-cell population. In Figures 3c and d , T2 and AT2 cell lines maintained higher concentration of topotecan than EV. However, they did exhibit similar levels of topotecan uptake with the existence of ABCG2 inhibitor fumitremorgin C, which demonstrated the difference in topotecan uptake between T2 or AT2 and EV is ABCG2 dependent. Further analysis of cell viability following long treatment with the two cytotoxic agents, doxorubicin and topotecan, consistently showed that T2 and AT2 cells had significantly higher sensitivities to both drug treatments over a range of drug concentrations when compared with EV control (Figures 3e and g ). Also at statistically significant increase in apoptotic events (activated caspase 3/7) were observed after treatment with 0.5 mg/ml of doxorubicin (Figure 3f ) or 1 mg/ml topotecan (Figure 3h ) in T2 and AT2 compared with EV controls. These results show that enhanced expression of TIMP-2 increases cell chemosensitivity, and that the underlying mechanism is attributed to a TIMP-2-mediated decrease in ABC transporter expression including ABCG2.
SP isolated from T2 or AT2 A549 cells has decreased regeneration and migration capacity in vitro compared with A549 controls In Supplementary Figures S2a and b , we showed that SP from wild-type A549 is more resistant to drug treatment as measured by apoptotic capase 3/7 assay, and formed more colonies than MP (the major cell population), which are consistent with the previously reported phenotype of A549 SP and MP. 22, 23 We then studied the effects of TIMP-2 on sorted A549 T2 and AT2 SP and MP fractions. SP and MP were isolated from the A549 cell lines by fluorescence-activated cell sorting (FACS) and analyzed for TIMP-2 mRNA expression using quantitative reverse transcriptase-PCR (Figure 4a ). The baseline TIMP-2 levels were similar in both SP and MP in the EV control cells, but markedly increased (4-to 8-fold) in the T2 and AT2 cell lines. We investigated the difference in phenotypic and functional properties of sorted SP from EV control, T2 or AT2. In SP regeneration experiments, sorted SP and MP were cultured for 1 week before re-staining with Hoechst dye and FACS analysis. As shown in Figures 4b and c , sorted SP from T2 or AT2 regenerated cell populations contained significantly less SP than sorted SP from EV after 1-week culture, whereas, sorted MP regenerated both SP and MP in all three cell lines with no significant differences between cell types. This experiment suggests that TIMP-2 overexpression suppresses the regeneration 6 / ml) were incubated with 100 mM of topotecan with or without 10 mM of ABCG2 inhibitor fumitremorgin C (FTC) (Sigma-Aldrich) in prewarmed Dulbecco's modified Eagle's medium/F-12 media 1:1 with 2% fetal bovine serum (FBS) and 10 mM HEPES buffer at 37 1C for 20 min, washed with ice-cold HBSS with 2% FBS and 10 mM HEPES buffer, and analyzed by flow cytometry for topotecan fluorescence. The assay was repeated three times as independent experiments. Differences between groups were tested for statistical significance using Student's t-test. *Po0.05 as compared with the EV treated with topotecan. (e, g) Cell viability of A549 T2, AT2 and EV cell lines was measured using a proliferation assay, WST (Biovision, Mountain View, CA, USA), after treatment with doxorubicin (Sigma, D1515) and topotecan (Sigma, T2705). A total of 3000 of cells were seeded in 96-well plate in six replicates overnight, and treated with increasing doses (0.06-1 mg/ml) of doxorubicin and topotecan. Cell viability was determined at 48 h according to the manufacturer's instructions. The experiment is representative from three independent experiments and was presented as the mean ± s.e.m. of six replicates. Differences between groups were tested for statistical significance using Student's t-test. **Po0.01 and ***Po0.001 as compared with the EV treated with the same dosage of doxorubicin or topotecan. (f, h) Drug-induced apoptosis of A459 cell lines were detected through measuring apoptotic cell markers, caspase 3 and 7, using Caspase-Glo 3/7 Assay (Promega, Milwaukee, WI, USA). The experiment was performed in 96-well plate and followed the protocol provided by the manufacturer. Briefly, 3000 cells were set up overnight, and treated with 0.5 mg/ml of doxorubicin or 1 mg/ml of topotecan for 48 h. At the end of each treatment, 100 ml of Caspase-Glo 3/7 reagent was added. The plate was incubated at room temperature for 30 min to 1 h before measuring the luminescence in plate-reading luminometer (Tecan, Research Triangle Park, NC, USA, infinite M200). The experiment was repeated at least three times. The representative experiment is shown as the mean ± s.e.m. of three replicates. Differences between groups were tested for statistical significance using Student's t-test. *Po0.05 and **Po0.01 as compared with the EV treated with doxorubicin or topotecan.
Endogenous suppressor of tumor side population H Han et al of SP in A549 cells, and this mechanism may contribute to the reduced tumorigenicity of high TIMP-2-expressing tumor cell lines observed in vivo.
20
TIMP-2 inhibits migration and invasion of A549 cells in vitro.
Studies by Ho et al. 11 show that the SP from lung cancer cell lines, including A549, are significantly more invasive than non-SP. To determine whether TIMP-2 reduces the migration of SP, we performed migration assays using the FACS isolated SP and MP from all three A549 cell lines. Indeed, the SP was more migratory than the MP in all three A549 cell lines evaluated (Figure 4d) . Furthermore, A549 T2 or AT2 showed statistically significant lower migratory activity in both the sorted SP and MP.
Endogenous suppressor of tumor side population H Han et al Figure 4 . SP from T2 or AT2 A549 cell lines regenerates less SP than from EV, and SP or MP from T2 and AT2 showed less migratory ability than from EV. (a) TIMP-2 levels in both SP and MP from T2 and AT2 A549 are 4-to 8-fold more than in EV. Real-time qPCR for TIMP-2 in sorted SP and MP from A549 cell lines and statistically analysis followed were performed as Figure 1 described. (b, c) SP from T2 and AT2 generated less SP compared with the SP from EV, and MP from all the stables still remained majority of MP cells after cultured for 1 week. SP and MP were sorted from A549 T2, AT2 and EV following the protocol as Figure 1 described. The sorted cells were cultured for 1 week before restaining with Hoechst dye and reanalyzed. The data in Figure 4c are the means±s.e.m. of three independent experiments. (d) Overexpressing TIMP-2 or Ala þ TIMP-2 decreased migratory ability of both SP and MP. Cell migration was measured using the disposable 96-well cell migration ChemoTx System (NeuroProbe, Gaithersburg, MD, USA) with an 8 mm pore, polycarbonate uncoated membrane. Sorted cells were cultured in complete media for 24-48 h for recovery from Hoechst staining, then followed the protocol as described in previous study. 20 The representative experiment from two independent experiments is shown as the mean ± s.e.m. of three replicates. Statistical analysis using Student's t-test was performed. *Po0.05, **Po0.01 and ***Po0.001 as compared with SP or MP in EV. (e-g) Genes regulated in whole population of A549 cells by overexpressing TIMP-2 and Ala þ TIMP-2 were also regulated in the same way in both SP and MP. Real-time qPCR for ABCG2, ABCB1 and AKR1C1 in sorted SP and MP from T2, AT2 and EV and statistically analyses were performed as described in Figure 1 .
We next analyzed transporter gene and AKR1C1 expression in FACS generated SP and MP (Figures 4e-g ). In EV control, ABCG2 and AKR1C1 expression was higher in sorted SP than MP, which is an agreement with previous studies. 11, 21 Interestingly, a decrease in expression of all three genes, ABCG2, ABCB1 (low expression levels in A549 cells) and AKR1C1, was detected in both the SP and MP with high TIMP-2 or Ala þ TIMP-2 levels (Figures 4e-g ), with the single exception of AKR1C1 expression in the T2 SP. Based on these findings, we suggest that the overexpression of TIMP-2 not only reduces SP percentage, but also affects the SP regenerative and migratory properties, along with the SP-associated gene expression in SP fractions.
Accumulating data support the concept that SP in human cancers is a potential target for novel cancer therapies. The SP from lung cancer cell lines demonstrates CSC characteristics as indicated by increased tumor-initiating capability, drug resistance and invasive potential in comparison with MP. 11 Studies on differential gene expression profiles performed in SP and MP from lung cancer cell lines show that a number of genes overexpressed in SP are associated with CSC characteristics and chemoresistance, including ABCG2 (an ABC transporter), AKR1C1/C2 and SOX1/2.
11,21,24
ABC transporters such as ABCG2 are overexpressed in stem-like lung cancer cells, 25 and are used as markers for this population. Although there is no evidence to suggest that ABCG2 is oncogenic, it is well recognized that ABCG2 mediates multidrug resistance of cancer cells to cytotoxic therapeutics. 16 High levels of both ABCC2 and ABCG2 expression are predictive of poor prognosis following cisplatin treatment, and patients with tumors that stained positive for ABCG2 tended to respond less well to therapy. 26 In a recent report, AKR1C1 is the most significantly upregulated gene in the A549 SP compared with the MP based on the microarray analysis of differential gene expression between these two populations. 21 Previous studies have claimed that AKR1C1 is associated with anticancer drug resistance in various human cancers. 27, 28 The biological role of TIMP-2 in tumor progression is considered by many to be principally mediated via MMP inhibitory activity. However, we have recently reported that overexpression of TIMP-2 and the mutant Ala þ TIMP-2 (lacking MMP inhibitory activity) in A549 cells results in significantly reduced tumor growth in vivo. These findings demonstrate that MMP-independent mechanisms have a role in TIMP-2-mediated inhibition of tumor growth. As TIMP-2 is mainly produced by normal stromal cells (endothelial and fibroblasts) these finding suggest that normal components of the tumor microenvironment may function to suppress tumor invasion and progression. 29, 30 In this study, we show that the proportion of the SP in six human lung cancer cell lines has a significant inverse correlation with the expression of endogenous TIMP-2. This observation led us to posit that the decreased SP fraction associated with increased TIMP-2 expression contributes to the decrease in tumor growth in vivo. 20 After examining the percentage and phenotype of the SP in A549 cell lines expressing high levels of TIMP-2 or Ala þ TIMP-2, we found that the SP fraction was significantly reduced. Furthermore, the expression of ABC transporter genes (ABCG2, ABCB1) was also suppressed, which might contribute to the enhanced sensitivity to cytotoxic drugs. These results suggest that TIMP-2 may potentially have synergistic effects when combined with other anticancer drugs. Moreover, SP function was impaired by the expression of TIMP-2 and Ala þ TIMP-2 as demonstrated by the reduced migration and regeneration of the SP population in FACS isolated SP and MP fractions. These data are the first evidence to suggest that TIMP-2 alters the SP-associated CSC phenotype and function in human cancers, and may provide a novel mechanism for TIMP-2 antitumor activity.
In conclusion, we show for the first time an inverse correlation between TIMP-2 mRNA expression levels and SP percentage, as well as reduced ABC transporter gene expression in A549 lung cancer cells. These data suggest that downregulation of ABCG2, and consequently reduction of SP percentage by TIMP-2 in A549 cells, may provide a novel mechanism for the antitumor effects of TIMP-2. These findings support the emerging paradigm that soluble components of the normal microenvironment, such as TIMP-2, can influence the CSC phenotype and tumor cell function.
